India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#426- Valuation
- ₹11,750 Cr
2023 #344 2022 #341 2021 #407
Revenue · FY 2025
₹1,870.29 Cr
▲ 12% YoY
Net profit · FY 2025
₹180.38 Cr
Net margin 9.6%
EBITDA · FY 2025
₹478.48 Cr
EBITDA margin 25.6%
Authorised capital
₹250 Cr
Registered with MCA
Paid-up capital
₹216.99 Cr
Issued & subscribed
Open charges
₹583.8 Cr
Satisfied ₹768.38 Cr
Company age
26 yrs
Est. 2000
Employees · EPFO
3,859
Provident fund records
About Aragen Life Sciences Limited
Data last updated:
Aragen Life Sciences Limited is a public limited company based in Hyderabad, Telangana, India. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 07 December 2000 and has been in existence for over 26 years.
Its director Davinder Singh Brar is #852 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U74999TG2000PLC035826. Its GSTIN is 36AABCG3208J1ZT (Telangana). The company holds 12 GST registrations, of which 6 are active.
The company has an authorised share capital of ₹250 Cr and a paid-up capital of ₹216.99 Cr. It was formerly known as Gvk Biosciences Private Limited. It is led by directors including Manmahesh Kantipudi (Managing Director) and Davinder Singh Brar.
Its last annual general meeting (AGM) was held on 27 June 2025, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Plot 28A Ida Nacharam, Hyderabad, Telangana, India – 500076.
As per the financials filed for FY 2025, the company reported a revenue of ₹1,870.29 Cr, a growth of 12% compared to the previous year. For the same year it recorded a net profit of ₹180.38 Cr (net margin 9.6%) and EBITDA of ₹478.48 Cr (EBITDA margin 25.6%). Revenue has grown at a compounded annual rate (CAGR) of 10% over three years and 14% over five years.
The company has about 3,859 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.
The company is associated with 2 brands: GVK Davix Technologies and Aragen Life Sciences. As per MCA filings, the company has open charges of ₹583.8 Cr and satisfied charges of ₹768.38 Cr on record. Court records list 31 cases involving the company, including 10 filed by the company and 21 filed against it; 9 cases are pending. The company has 26 deals on record (21 secondary share transfers, 4 funding rounds, 1 acquisition), with disclosed funding of ₹1,040.25 Cr; the latest was in August 2025. The company has 46 MSME Form 1 returns on record between 2010 and 2024, listing 19,298 overdue payments to 864 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website gvkbio.com.
Company details
CIN U74999TG2000PLC035826
Registration Number 035826
Incorporation Date 07 December 2000
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 27 June 2025
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
CIN history
Aragen Life Sciences has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U74999TG2000PLC035826, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U74999TG2000PLC035826 | Current |
| U74999AP2000PTC035826 | Previous |
| U74999TG2000PTC035826 | Previous |
Key People
Manmahesh Kantipudi Managing Director Sachin Anand Dharap Cfo Davinder Singh Brar Director Recognitions & Rankings of Aragen Life Sciences
India's Richest People 2026 edition · 1 director · Source: Hurun India
- #852 Davinder Singh Brar ₹3,500 Cr
Contact details
Aragen Life Sciences Limited's registered office is in Hyderabad, Telangana. Its website is gvkbio.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressPlot 28A Ida Nacharam, Hyderabad, Telangana, India – 500076
- IndustryPharma, Pharma Contract R&D
To see the full contact details of Aragen Life Sciences Limited, buy the company report.
Comprehensive company report
Aragen Life Sciences Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Aragen Life Sciences operates two associated brands: GVK Davix Technologies and Aragen Life Sciences. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Provider of drug preclinical and formulation development services | gvkbio.com | |
| Aragen Life Sciences is engaged in contract research and manufacturing for pharmaceuticals. | aragen.com |
Business activity
The main business activities of Aragen Life Sciences are professional, scientific and technical and manufacturing. In detail, this covers scientific research and development and chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development | |
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Aragen Life Sciences Limited, buy the company report.
Financials of Aragen Life Sciences Limited
FY 2024 filings availableAragen Life Sciences Limited reported revenue of ₹1,870.29 Cr (up 12% YoY) for FY 2025.
Revenue · FY 2025
₹1,870.29 Cr ▲ 12%
Net profit · FY 2025
₹180.38 Cr margin 9.6%
EBITDA · FY 2025
₹478.48 Cr margin 25.6%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 12%
3 years · compounded
▲ 10%
5 years · compounded
▲ 14%
EBITDA CAGR growth
1 year
▲ 6%
3 years · compounded
▲ 4%
5 years · compounded
▲ 14%
Revenue has grown at a compounded annual rate (CAGR) of 14% over five years, including 12% growth in the latest year. EBITDA rose 6% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹478.48 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹180.38 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 25.6% | ||||
| Net Profit Margin | 9.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Aragen Life Sciences Limited, buy the company report.
Board of directors and KMP of Aragen Life Sciences Limited
Aragen Life Sciences Limited currently reports 8 directors and 1 key managerial person. 19 former directors have served the organization.
Current Directors and KMP
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Davinder Singh Brar Also directs: Epl Limited, Mountain Trail Foods Private Limited, Madhubani Investments Private Limited and 5 more | Director | 26 Jul 2004 | 22 Years 2 Months | Current |
| Amit Varma Also directs: Cnext Health Solutions LLP, Encube Ethicals Private Limited, Nobel Hygiene Private Limited and 5 more | Director | 09 Jan 2025 | 1 Years 9 Months | Current |
| Ajay Srivastava | Director | 20 May 2021 | 5 Years 5 Months | Current |
| Anita Ramachandran | Director | 07 Nov 2022 | 3 Years 11 Months | Current |
| Rajat Sood Also directs: Girnar Insurance Brokers Private Limited, Girnar Finserv Private Limited, Peoplestrong Technologies Private Limited and 1 more | Director | 19 May 2021 | 5 Years 5 Months | Current |
| Manmahesh Kantipudi Also directs: Intox Private Limited, Aragen Biologics Private Limited, Zeroharm Sciences Private Limited and 2 more | Managing Director | 29 May 2018 | 8 Years 4 Months | Current |
Showing 6 of 9 current directors and KMP. View all directors and KMP
Auditor
Aragen Life Sciences Limited is audited by BSR & Co for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| BSR & Co | FY 2024 | 128510W |
Shareholding
The shareholding of Aragen Life Sciences Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Aragen Life Sciences Limited, buy the company report.
Charges & borrowings
Open charges
₹583.8 Cr
Satisfied charges
₹768.38 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 15 Apr 2025 | 101090128 | Citi Bank N.A. | ₹100 Cr | Open | |
| 28 Mar 2024 | 100902297 | Others | ₹50 Cr | Open | |
| 07 Dec 2021 | 100517767 | Citi Bank N.A. | ₹50 Cr | Open | |
| 08 Nov 2021 | 100505209 | Others | ₹100 Cr | Open | |
| 31 Mar 2020 | 100333813 | Others | ₹75 Cr | Open |
To see the full charge records of Aragen Life Sciences Limited, buy the company report.
Total charge records: 27 View all charges
Deals & funding
Aragen Life Sciences Limited has 26 deals on record (21 secondary share transfers, 4 funding rounds, 1 acquisition), with disclosed funding of ₹1,040.25 Cr; the latest was in August 2025.
Total deals
26
Secondary share transfers
21
Funding rounds
4
Acquisition
1
Disclosed funding
₹1,040.25 Cr
Deals on record (5 of 26)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Aug 2025 | Funding round | ₹300 Cr | Investors: Avendus Capital, Sbi Life Insurance Company Limited |
| Dec 2006 | Secondary share transfer | Undisclosed | Buyer: 3 individuals Seller: Madhubani Investments Private Limited , 2 individuals |
| Dec 2006 | Funding round | ₹6.5 Cr | Investors: GVK Davix Technologies Private Limited , 3 individuals |
| Mar 2006 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: GVK Davix Technologies Private Limited , 3 individuals |
| Dec 2005 | Acquisition | ₹1.98 Cr | Buyer: GVK Davix Technologies Private Limited |
To see the full deal history of Aragen Life Sciences Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Aragen Life Sciences Limited has 31 court cases on record: 10 filed by Aragen Life Sciences, 21 filed against it. 9 cases are pending and 22 are disposed.
Total cases
31
Filed by the company
10
Filed against the company
21
Pending
9
Disposed
22
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 18 | 13 | 8 |
| District courts | 13 | 8 | 1 |
Cases on record (5 of 31)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Medchal Malkajgiri, Telangana | Civil suit | Filed against the company by Intonation Research Laboratories Pvt. Ltd., Rep.By Its Laxmi Naresh Reddy Yarra | Pending |
| District court, Mumbai City Civil Court, Maharashtra | Interim or miscellaneous application | Filed against the company by Systime Global Solutions Pvt Ltd | Disposed |
| High Court, TELANGANA | Company petition | Filed against the company by M/S. Leo Hospitality Management Services India Pvt. Ltd., | Disposed |
| High Court, TELANGANA | Court case (ITTA) | Filed by the company against Assistant Commissioner of Income Tax | Pending |
| High Court, TELANGANA | Court case (ITTA) | Filed against the company by The Principal Commissioner of Income Tax-2 | Pending |
To see the full case history of Aragen Life Sciences Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Aragen Life Sciences Limited was last rated by Crisil on 28 Sep 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 28 Sep 2021 |
To see the full credit ratings and regulatory alerts of Aragen Life Sciences Limited, buy the company report.
MSME payment delays
Aragen Life Sciences Limited has 46 MSME Form 1 returns on record between 2010 and 2024, listing 19,298 overdue payments to 864 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 864)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Sun Tech Precision | |||
| Dekra India Private Limited | |||
| Panchami Logistics and Enterprises | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Aragen Life Sciences Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Aragen Life Sciences has 2 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
2
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Intox Private Limited | U74999PN2000PTC015116 | |
| Aragen Foundation | U85300DL2021NPL391515 |
To see the full group structure of Aragen Life Sciences Limited, buy the company report.
Employees & EPFO
Aragen Life Sciences Limited has a workforce of 3,859 employees on its EPFO records as of Apr 08, 2024, across 1 active EPFO establishment.
Employee count
3,859
Active EPFO establishments
1
Employee growth
-1.71%
GST
Aragen Life Sciences has 12 GST registrations: 6 active and 6 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
12
Active
6
Cancelled / inactive
6
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AABCG3208J1ZT | Telangana | Active | 01 Jul 2017 |
| 36AABCG3208J2ZS | Telangana | Active | 28 Dec 2021 |
| 07AABCG3208J1ZU | Delhi | Active | 01 Jul 2017 |
| 29AABCG3208J1ZO | Karnataka | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Aragen Life Sciences Limited, buy the company report.
Recent activity
Aragen Life Sciences Limited has 28 board changes on record since 2004: 9 appointments and 19 cessations. The latest: Amit Varma ceased to be Additional Director on 10 Jan 2025.
Charges
A charge registered on 17 Aug 2023 via Charge ID 100774202 with Citi Bank N.A. was fully satisfied on 20 Sep 2025.
AGM
Aragen Life Sciences Limited last Annual general meeting of members was held on 27 Jun 2025 as per latest MCA records.
Charges
A charge with Citi Bank N.A. amounted to Rs. 100.00 Cr with Charge ID 101090128 was registered on 15 Apr 2025.
Charges
A charge with Others of Rs. 100.00 Cr registered on 08 Nov 2021 with Charge ID 100505209 was modified on 26 Mar 2025.
Charges
A charge registered on 10 Feb 2022 via Charge ID 100558920 with Idbi Trusteeship Services Limited was fully satisfied on 20 Mar 2025.
Ceased
Amit Varma ceased to be Additional Director.
Appointed
Amit Varma was appointed as Director.
Charges
A charge with Others of Rs. 100.00 Cr registered on 28 Jul 2006 with Charge ID 10013686 was modified on 15 Oct 2024.
Charges
A charge registered on 06 Sep 2002 via Charge ID 90124333 with Canara Kbank was fully satisfied on 18 Jul 2024.
Charges
A charge registered on 24 Sep 2021 via Charge ID 100490209 with Others was fully satisfied on 28 Jun 2024.
Charges
A charge registered on 06 Mar 2019 via Charge ID 100249973 with Others was fully satisfied on 02 Apr 2024.
Filing
Aragen Life Sciences Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad.
74 earlier events are in the company report.
News
Frequently asked questions
Aragen Life Sciences is an active public limited company based in Hyderabad, Telangana, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 07 December 2000 (26+ years old) and is registered under CIN U74999TG2000PLC035826.
Aragen Life Sciences has 9 current directors and KMP:
- Manmahesh Kantipudi - Managing Director
- Davinder Singh Brar - Director
- Amit Varma - Director
- Ajay Srivastava - Director
- Anita Ramachandran - Director
- Rajat Sood - Director
- Robert Richard Ruffolo - Director
- Gunapati Reddy Venkat Keshav - Director
- Sachin Anand Dharap - Cfo
The latest financial statements of Aragen Life Sciences on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 27 June 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Aragen Life Sciences is 36AABCG3208J1ZT, registered in Telangana. The company has 12 GST registrations in all, of which 6 are active and 6 are cancelled or inactive. Other active GSTINs include 36AABCG3208J2ZS (Telangana), 07AABCG3208J1ZU (Delhi), 29AABCG3208J1ZO (Karnataka).
The CIN (Corporate Identification Number) of Aragen Life Sciences is U74999TG2000PLC035826. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Aragen Life Sciences has 31 court cases on record: 10 filed by the company and 21 filed against it. 9 are pending. Most are in the high courts.
Aragen Life Sciences was incorporated on 07 December 2000, making it 26+ years old. It is registered with the Registrar of Companies, Hyderabad.
Aragen Life Sciences has 26 deals on record (21 secondary share transfers, 4 funding rounds, 1 acquisition), with disclosed funding of ₹1,040.25 Cr; the latest was in August 2025.
Amit Varma ceased to be Additional Director on 10 Jan 2025. Amit Varma was appointed as Director on 09 Jan 2025. Sachin Anand Dharap was appointed as CFO on 25 Jan 2023. Aragen Life Sciences has 28 board changes on record in total.
Aragen Life Sciences has 46 MSME Form 1 returns on record between 2010 and 2024, listing 19,298 overdue payments to 864 micro and small suppliers. The latest return was filed on 01 May 2024.
Aragen Life Sciences can be reached through the website gvkbio.com. Its registered office is in Hyderabad, Telangana, India.